NCT03609593
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03609593
Title Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nicole Lamanna
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital New York New York 10032 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field